Collegium 2025 Financial Guidance and Business Update

 – Product Revenues, Net Expected in the Range of $735 Million to $750 Million –

– Jornay PM® Net Revenue Expected to be in Excess of $135 Million –

– Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million –

– Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million –

“In 2024, we executed on our priorities of maximizing the pain portfolio and strategically deploying capital, delivering record financial results and closing the acquisition of Ironshore,” said Vikram Karnani, President and Chief Executive Officer of Collegium. “Looking ahead to 2025 and beyond, Collegium will embark upon a new phase of growth. Jornay PM, as a highly differentiated product to treat ADHD, is positioned to be our lead growth driver, and our focus will be on commercial expansion. We are committed to maximizing and delivering strong performance across our entire portfolio as we build a leading, diversified biopharmaceutical company serving people living with serious medical conditions.”

“Our 2025 financial guidance reflects expected significant top- and bottom-line growth driven by the addition of Jornay PM and continued performance from our pain portfolio. We expect Jornay PM net revenue in 2025 to be in excess of $135 million,” said Colleen Tupper, Chief Financial Officer of Collegium. “We plan to make targeted investments in Jornay PM throughout 2025, which we expect will accelerate growth in the near-term, while creating significant momentum in 2026 and beyond. In addition, we will continue to strategically deploy capital in a disciplined manner to create long-term value for our shareholders.”

Financial Guidance for 2025

• Product revenues, net are expected in the range of $735 million to $750 million.
• Adjusted EBITDA (excluding stock-based compensation) is expected in the range of $435 million to $450 million.
• Adjusted operating expenses (excluding stock-based compensation) are expected in the range of $220 million to $230 million.
  

* Non-GAAP financial measure. Please refer to the “Non-GAAP Financial Measures” section for details regarding these measures.

https://www.globenewswire.com/news-release/2025/01/08/3006178/34897/en/Collegium-Provides-2025-Financial-Guidance-and-Business-Update.html